Synthego debuts CRISPR-based cell engineering platform

By The Science Advisory Board staff writers

April 7, 2021 -- Synthego has launched Eclipse, a high-throughput, CRISPR-based cell engineering platform aimed at accelerating drug discovery and validation.

The Eclipse platform is scalable and aims to enhance disease modeling and drug target identification and validation, and to accelerate cell therapy manufacturing. Eclipse uses machine learning combined with automation to make edits across hundreds of cell types.

Synthego's Eclipse platform enables scalable CRISPR-based cell engineering. Image courtesy of Synthego.

The platform is engineered to use a cell-type agnostic process and aims to benefit researchers working with induced pluripotent stem (iPS) cells and immortalized cell lines.

Synthego introduces new CRISPR light control tech
Synthego has designed a new foundational technology for standardized precision and control of CRISPR-based genome editing inside cells using light.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter